Ann M. Hanly - 22 Feb 2023 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role: Chief Technology Officer
Signature: /s/ Howard Horn, Attorney-in-Fact
Issuer symbol: VIR
Transactions as of: 22 Feb 2023
Transactions value $: -$59,790
Form type: 4
Date filed: 24 Feb 2023, 19:35
Previous filing: 31 Mar 2022
Next filing: 31 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VIR	Common Stock	Award	$0	+37.5K	+45.73%	$0.00	120K	22 Feb 2023	Direct	F1, F2
transaction	VIR	Common Stock	Sale	-$59.8K	-2.3K	-1.93%	$25.97	117K	23 Feb 2023	Direct	F3
holding	VIR	Common Stock						11.5	22 Feb 2023	See footnote	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIR	Stock Option (Right to Buy)	Award	$0	+55K		$0.00	55K	22 Feb 2023	Common Stock	55K	$27.01	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2	Includes 532 shares of common stock acquired by the reporting person on May 31, 2022 pursuant to an employee stock purchase program.
F3	Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
F4	The shares are beneficially owned by the reporting person's spouse, for the benefit of a minor child.
F5	25% of the shares subject to the stock option vest and become exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter.